======= ILF2 =======
== Gene Information ==
* **Official Symbol**: ILF2
* **Official Name**: interleukin enhancer binding factor 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3608|3608]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q12905|Q12905]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=ILF2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ILF2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/603181|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Appears to function predominantly as a heterodimeric complex with ILF3. This complex may regulate transcription of the IL2 gene during T-cell activation. It can also promote the formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA. Essential for the efficient reshuttling of ILF3 (isoform 1 and isoform 2) into the nucleus. {ECO:0000269|PubMed:10574923, ECO:0000269|PubMed:11739746, ECO:0000269|PubMed:21123651, ECO:0000269|PubMed:9442054}.
|DZF|
|tertiary granule lumen|
|transferase activity|
|specific granule lumen|
|double-stranded RNA binding|
|ficolin-1-rich granule lumen|
|ribonucleoprotein complex|
|neutrophil degranulation|
|neutrophil activation involved in immune response|
|neutrophil mediated immunity|
|neutrophil activation|
|granulocyte activation|
|leukocyte degranulation|
|myeloid leukocyte mediated immunity|
|myeloid cell activation involved in immune response|
|myeloid leukocyte activation|
|leukocyte activation involved in immune response|
|cell activation involved in immune response|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|regulated exocytosis|
|leukocyte mediated immunity|
|exocytosis|
|nucleolus|
|leukocyte activation|
|secretion by cell|
|export from cell|
|cell activation|
|immune effector process|
|nucleobase-containing compound biosynthetic process|
|secretion|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|organic cyclic compound biosynthetic process|
|RNA binding|
|DNA binding|
|ATP binding|
|positive regulation of transcription, DNA-templated|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|positive regulation of RNA metabolic process|
|macromolecule biosynthetic process|
|immune response|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|extracellular region|
|vesicle-mediated transport|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|membrane|
|gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|-2.02|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|1.81|
^Gene^Correlation^
|[[:human genes:i:ints6|INTS6]]|0.448|
|[[:human genes:c:cdc73|CDC73]]|0.446|
|[[:human genes:r:rbm39|RBM39]]|0.428|
|[[:human genes:c:ctr9|CTR9]]|0.42|
|[[:human genes:b:brd2|BRD2]]|0.417|
Global Fraction of Cell Lines Where Essential: 524/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|1/1|
|bile duct|22/28|
|blood|23/28|
|bone|16/26|
|breast|19/33|
|central nervous system|42/56|
|cervix|3/4|
|colorectal|11/17|
|esophagus|8/13|
|fibroblast|1/1|
|gastric|11/16|
|kidney|16/21|
|liver|12/20|
|lung|47/75|
|lymphocyte|11/16|
|ovary|21/26|
|pancreas|20/24|
|peripheral nervous system|11/16|
|plasma cell|9/15|
|prostate|1/1|
|skin|18/24|
|soft tissue|6/9|
|thyroid|2/2|
|upper aerodigestive|15/22|
|urinary tract|24/29|
|uterus|3/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 417
* **Expression level (log2 read counts)**: 8.23
{{:chemogenomics:nalm6 dist.png?nolink |}}